NICE has already approved use of lanadelumab for this population, only if they are eligible for preventive C1-esterase inhibitor treatment in line with NHS England's commissioning policy, that is, they are having 2 or more clinically significant attacks per week over 8 weeks despite oral preventive therapy, or oral therapy is contraindicated or not tolerated.